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LETTERS TO THE EDITOR 1733The index datewas defined as the date of the first indicator of dia-
betes for cases and the date of selection for controls. The dose of
ICSs was categorized as low (<251 mg/d, fluticasone propionate
equivalents), medium (251-500 mg/d), high (>500 mg/d), or no
use, and LABAwas classified as use (>_1 mg/d, salmeterol equiv-
alents) or no use and measured on the index date. This study was
approved by the Research and Ethics Committee of the Ho^pital du
Sacre-Cœur de Montreal and by the Commission d’acces a l’in-
formation du Quebec. For additional methodological details,
see this article’s Online Repository at www.jacionline.org.
We identified 1001 cases of GD and selected 30,030 controls
without GD among the 12,587 pregnancies of women with
asthma (see Fig E1 in this article’s Online Repository at www.
jacionline.org). The cases were older and more likely to have un-
controlled asthma and a history of GD (see Table E3 in this arti-
cle’s Online Repository at www.jacionline.org). The generalized
estimation equations models (Table I) indicate that the dose of
ICSs among nonusers of LABAs was not significantly associated
with GD. Moreover, adding LABAs to ICSs did not increase the
risk of GD compared with ICSs alone. We also found that women
who used a medium ICS dose without a LABAwere not signifi-
cantly at a higher risk of GD than women who used a low ICS
dose plus a LABA. Moreover, the risk of GD was found similar
between women who used a high ICS dose without a LABA
and those who used a medium ICS dose plus a LABA.
Strengths of this study include a large sample size, avoiding
recall bias, and fixing cohort entry at week 20 of gestation to avoid
index event bias. Fixing cohort entry at pregnancy onset could
have biased the odds ratios toward the null in case ICSs or LABAs
would be associated with early pregnancy termination. Neverthe-
less, unmeasured covariates such as ethnicity, obesity, and
familial history of GD may cause residual confounding if they
are associated with the use of ICSs or LABAs. The indications for
antiasthmatic medications may also introduce residual confound-
ing because higher ICS doses or the addition of LABAs is likely to
be prescribed to those with more severe asthma. However, despite
this potential bias, the adjusted odds ratios associated with
medium and high ICS doses and with LABAs remained close to
the null and not statistically significant.
Our results provide further evidence on the safety of LABAs
and ICSs during pregnancy with no significantly increased risk of
GD detected among women exposed to those medications.
Although not statistically significant, the adjusted odds ratios
associated with moderate and high doses of ICS were slightly
greater than 1, and it might be due to residual confounding by
obesity or asthma severity. More studies with better adjustment
capacity for obesity and asthma severity are needed to further
examine the association between higher ICS doses and the risk of
GD in women with asthma.
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MHC class I deficiency corrects
T-cell immunity but dissociates
natural killer cell repertoire
formation from functionTo the Editor:
The examination of primary immunodeficiency represents an
opportunity to gain unique insights into models of human
immunity.1MHC class I deficiency is a primary immunodeficiency
in which both innate and adaptive immune systems are
compromised because of the effects of absent MHC class I on
CD81 T-cell and natural killer (NK)-cell development and
function.2 The most frequent cause of MHC class I deficiency is
loss of the TAP1 or TAP2 proteins. These proteins import
peptides from the cytoplasm to MHC class I molecules within the
endoplasmic reticulum, supporting their peptide-loading and cell
surface expression. CD81 T cells require MHC class I expression
for their thymic selection and development. Mature CD81 T cells
target infected tissues by recognizing foreign peptides presented
byMHC class I molecules on the surface of infected cells. NK cells
also require MHC class I engagement for full functional
development during their ontogeny.3 However, once fully
functional, NK-cell effector functions are inhibited by MHC
class I.4
We describe the successful outcome and normalization of
T-cell immunity after the first allogeneic stem cell transplant for
MHC class I deficiency. The child, born in Pakistan to first cousin
parents, presented at the age of 6 years with a 2-year history of
recurrent Streptococcus pneumoniae andHaemophilus influenzae
chest infections, with radiological evidence of bronchiectasis.
From the age of 10 years, she developed chronic, slowly enlarging
skin ulcers over the extensor surfaces of both elbows (Fig 1, A).
Human herpes viruses and EBV were identified from skin
FIG 1. Clinical presentation of the patient showing pretransplant necrotic ulcer of the right elbow (A) and
posttransplant healed ulcer of the right elbow at 12months (B). C, Flow cytometry of MHC class I expression
on PBMCs taken pretransplantation and posttransplantation, compared with that of the father (HLA-A2/24;
HLA-B35/61; HLA-Cw4/Cw15). Isotype control (filled histograms) and specific anti-HLA antibodies
(black unfilled histograms) are shown together with the MFI of MHC class I expression. D, TAP expression
by intracellular flow cytometry of patient BLCL pretransplantation and posttransplantation compared with
that of the father, mother, and healthy control. Cells were stained for TAP1 (TAP1.28, unfilled histograms
black line), TAP2 (TAP2.17, unfilled histograms gray line), or relevant isotype control (filled histograms).
Histograms were gated on live lymphocytes. The MFI of the TAP1 and TAP2 expression is shown.
BLCL, EBV transformed lymphoblastoid B cell line; MFI, mean fluorescence intensity.
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viral types including cytomegalovirus (data not shown). The
ulcers failed to respond to antibiotics and antiviral agents.
A male second cousin, who had a similar clinical phenotype
with bronchiectasis and chronic skin ulcers, died at the age of
10 years of cor pulmonale secondary to severe chronic lung
disease.
Initial immune investigations revealed a distinctive phenotype
of a high CD4/CD8 ratio (10:1) with low numbers of CD81
T cells (0.29 3 109/L) and normal immunoglobulins (see Table
E1 in this article’s Online Repository at www.jacionline.org).
Because of the child’s poor clinical response to conventional
treatment, continued deterioration in respiratory function, skin
ulcers, abnormal immune function, and family history, she
underwent a stem cell transplantation for an undefinedimmunodeficiency. She was homozygous across the HLA
(A2402/2, B3502/2, Cw0401/2, DRB10301/2, DQB10201/2,
DPB10501/) and transplanted with a partially matched unrelated
female donor (A2407/2, B3503/2, Cw0401/2, DRB10301/2,
DQB10201/2, DPB10501/2) at the age of 13 years. This
followed low-intensity conditioning with campath 1H
0.2 mg/kg dose (34), fludarabine 30 mg/m2 dose (35),
and melphalan 140 mg/m2 dose (31). Her clinical course post-
transplantation was uncomplicated. At 6 months posttransplant,
the patient was 100% donor chimeric in both the myeloid and
lymphoid lineages. Her clinical condition had improved and the
large ulcers had healed (Fig 1, B).
In view of her clinical presentation, immunological abnormal-
ities, and homozygosity at the MHC, she was extensively
investigated for MHC class I deficiency.
FIG 2. A, Flow cytometric analysis of T-cell receptor Vb family expression on pretransplant and 12-month
posttransplant T cells (left panel) and on the CD4 or CD8 T-cell subsets posttransplant (right panel). The
frequencies of the individual Vb family within each subpopulation are shown as a percentage of that
particular subset. B, Comparison of NK-cell function pretransplant and posttransplant (18 months) with 3
healthy controls. Shown are the percentages of CD32veCD561veNK cells expressing either IFN-g by
intracytoplasmic cytokine staining or degranulating (CD107a expression) in response to IL-15, K562 or
IL-15 and K562, as determined by flow cytometry.
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Cw0401) on the patient’s pretransplant PBMCs showed a
reduction in surface MHC class I expression (Fig 1, C). This
expression was notably higher than that in previous reports
from patients with MHC class I deficiencies.5 Flow cytometry
using locus-specific antibodies for the TAP-dependent HLA-C
and HLA-E alleles demonstrated an absence of both alleles
(Fig 1, C). These 2 alleles are key ligands for NK-cell
ontogeny and function. The patient’s Cw0401 allele is cognate
for the KIR2DL1 receptor while HLA-E is recognized by
NKG2A; these are the only cognate MHC-KIR interactions
present in this individual. Evaluation of patient’s PBMCs using
intracellular flow cytometry for TAP1 and TAP2 proteins
demonstrated absence of both proteins pretransplant (Fig 1,
D). Molecular studies demonstrated truncation of TAP1
cDNA after exon 3 and complete absence of TAP2 cDNA.
Genomic DNA evaluation identified a homozygous deletion
from exon 3 of TAP1 through to exon 11 of TAP2, confirming
the first description of a combined TAP1 and TAP2 deficiency
(see Fig E1 in this article’s Online Repository at www.
jacionline.org).
Posttransplant the MHC class I expression returned to
normal (Fig 1, B) with restoration of TAP1 and TAP2 expres-
sion by flow cytometry (Fig 1, D). At 6 months posttrans-
plant, the CD81 T-cell population increased to 45% of
T cells and the CD4:8 ratio corrected to 1:1 (Table E1).We evaluated the TCR Vb profile posttransplant to establish
the reconstitution of a polyclonal repertoire of T cells. The
TCR profile of the posttransplant CD81 T cells at 1 year
showed broad representation of all T-cell receptor Vb family
members (Fig 2, A). Additional naive T-cell phenotyping
showed that 53% of CD41 and 11% of CD81 T cells were
naive. T-cell proliferation studies returned to normal, and all
parameters were stable over the first 36 months posttransplant
(Table E1).
The theoretical concern post–stem cell transplantation for
MHC class I deficiency is that donor NK cells will be
successfully reconstituted following cognate engagement
with MHC class I–competent hematopoietic tissue and this
may lead to deleterious self-reactivity with MHC class I–
deficient tissue. Post–stem cell transplantation, the NK-cell
distribution returned to normal representing 22% of lym-
phocytes, with 7% of them being CD56bright compared with
46% pretransplant (Table E1). NK cells also displayed a
different phenotype posttransplant whereby they lost the un-
usual phenotype of being multi-KIR positive, dropping from
43% pretransplant to less than 2% of NK cells (Table E1).
In addition, the posttransplant NK cells displayed a recon-
stitution of the expected single positive cognate
KIR2DL1:HLA-Cw4 population (Table E1). Despite these
changes in NK-cell phenotype, the functional deficiency of
the NK cells remained impaired posttransplant, showing
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degranulation assays against MHC class I–deficient target
cells (Fig 2, B).
In MHC class I deficiency, the NK-cell population has not
encountered cognate MHC class I ligands and fail to proceed to
full functional development.6-8 Similarly, CD8 T cells have failed
to be selected by MHC class I complexes within the thymus,
leading to poor development. In the posttransplant setting,
hematopoietic reconstitution has supported CD8 T-cell
development, leading to naive and TCR diverse populations.
For NK cells, there is evidence of engagement with the
restored MHC class I competence of the hematopoietic lineage,
leading to phenotypic change but this does lead to full
functional restoration. This NK-cell hypofunction may protect
against self-reactivity to MHC class I–deficient somatic tissue.
In summary, this patient has improved dramatically following
bone marrow transplant for MHC class I deficiency and
now exhibits a distinctive immune status with impaired NK
function but restored CD8 immunity that will require long-term
follow-up.
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conflicts of interest.FIG 1. HSNEC permeability assessed by TEER (A) and FITC-dextran (B) after
PM at 300 mg (Fig 1, A) or 150 mg and 300 mg (Fig 1, B) and SFN stimulation.
Comparing PM exposure to no PM exposure, *P < .05 and ***P < .001.
Comparing PM/vehicle to PM/SFN #P < .05 and ##P < .01. Error bars repre-
sent SEM of at least 3 independent experiments. RFU, Relative fluorescence
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http://dx.doi.org/10.1016/j.jaci.2016.06.029Air pollutant–mediated disruption
of sinonasal epithelial cell barrier
function is reversed by activation
of the Nrf2 pathwayTo the Editor:
Particulate matter (PM) is 1 of 6 damaging air pollutants that
has been identified under the United States Clean Air Act of 1970
and is regulated because of its harmful effects. PM directly
contain redox-active chemicals and transition metals that can
generate reactive oxygen species. The harmful effects of outdoor
PM are well established and include premature death, and both
indoor and outdoor PM have been documented to exacerbate
asthma morbidity.1 PM also has been reported to cause sinonasal
inflammation in both mouse and human models. Mice that were
challenged intranasally with PM showed nasal epithelial thick-
ening and increased eosinophils in nasal lavage.2 Furthermore,
human studies have also demonstrated that stimulating sinonasal
epithelial cells with PM causes increases in proinflammatory
cytokines.3
At the interface between the environment and exposure to air
pollutants is the sinonasal epithelial cell barrier, which acts to
limit the transit of noxious materials. Disruption of barrier
integrity and function may lead to persistent inflammation
FIG E1. A, RT-PCR of the different exons of TAP1 and TAP2 showing absence of TAP1 genes beyond exon 3
and complete absence of TAP2. RNA was extracted from BLCL of the patient, TAP positive (T0) and
TAP-negative (T2) control lines. Tapasin (*) was amplified as a loading control. B, PCR from genomic
DNA showing the presence of TAP1 up to exon 3 and the absence of TAP2 in the same cell lines as in
Fig E1, A.
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TABLE E1. Lymphocyte phenotype and in vitro proliferative responses at pretransplantation and posttransplantation time points
Subset Pretransplant Posttransplant Reference range
Lymphocytes (3109/L) 4.2 3.7 1-5
T-cell enumeration
CD4 (3109/L) 3.0 1.2 0.4-2.1
CD8 (3109/L) 0.29 0.9 0.2-1.2
CD4/CD8 ratio 10 1.3 1-3.6
Naive CD4 (% of CD41 T cells) 72 53 25-55
Naive CD8 (% of CD81 T cells) 88 11 10-50
TCR Vb expression 82 86 >70%
T-cell function
Unstimulated (cpm) 261* 288 1,435*/376
Anti-CD3 (cpm) 5,638* 136.617 158,306*/201,034
Anti-CD3 1 IL-2 (cpm) 477,291* 261,708 464,012*/280,034
PMA (cpm) 7,003* 125,751 299,981*/114,851
PMA 1 ionophore (cpm) 380,870* 177,818 291,281*/182,116
PHA (cpm) 146,845* 270,906 259,052*/271,222
ConA (cpm) 316,114* 227,533 256,313*/178,131
NK-cell enumeration (% NK cells)
NK cells (3109/L) 0.13 0.8 0.07-1.2
CD56bright NK cells (% NK cells) 46 7 1-10
Triple KIR/NKG2A1 NK cells 43 <2 <2
Cognate MHC-KIR1 NK cells <2 37 ND
Con A, Concanavalin A; cpm, counts per minute; ND, not determined; PHA, phorbol 12-myristate 13-acetate.
*Control value for pre.
Control values for postnaive T cells were identified as CD45RA CCR71ve. Triple KIR/NKG2A NK cells are represented by those that coexpress KIR 2DL1, 2DL2/3, and KIR
3DL1/NKG2A. Cognate MHC-KIR1 NK cells are represented by those coexpress KIR 2DL1 (cognate for cw0401).
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